ClinicalTrials.gg
Active, not recruitingNCT07217860Updated Oct 13, 2026

An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)

A Phase 3 interventional study of Azetukalner in Bipolar Depression, Bipolar I Disorder and Bipolar Disorder, sponsored by Xenon Pharmaceuticals Inc.. Active, not recruiting at 20 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Xenon Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment

Updated Oct 13, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 837 studies in Bipolar Disorder with a site in United States — 77 open to participants now, 96 under way, 8 of them phase 3. Bipolar Disorder · United States.

Planned enrollment
52nd of 704
400 · median 58
Started
2025
with 24 others
Phase 3
117 of 837
3 open now
Primary completion
2029-06
later than 82 of 94 live
Registered
821st of 837
by date

Among the 837 studies in Bipolar Disorder with a site in United States, this one is the 52nd largest by planned enrollment of the 704 interventional ones that give a count, is one of 25 that started in 2025, is one of 117 in phase 3, reaches primary completion later than 82 of the 94 other live ones, and was the 821st registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 267 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

77 of the 837 studies in Bipolar Disorder with a site in United States are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 205 Bipolar Disorder studies recruiting now, 59 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 37 take children under 18; 50 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 837 studies in Bipolar Disorder with a site in United States, or all of them as a file.
02

Study summary

X-CEED-OLE is a Phase 3, multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner in adult participants who successfully completed an antecendent Phase 3 azetukalner bipolar depression study.

03

Conditions studied

  • Bipolar Depression
  • Bipolar I Disorder
  • Bipolar Disorder
  • Bipolar II Disorder

Browse trials for

Keywords

  • Bipolar
  • XEN1101
  • Azetukalner
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant successfully completed the treatment period in a Phase 3 antecedent study evaluating azetukalner in participants with bipolar depression.
  • Participant provides written to participate in the study, is able to understand the procedures and study requirements, and agrees to abide by them.
  • Participant is willing to comply with the requirements.

Exclusion criteria

Exclusion Criteria:

  • Participant met any of the withdrawal criteria, discontinued study drug early, or was terminated early from an antecedent study.
  • Participant had any protocol deviations in an antecedent study that, in the opinion of the investigator, would preclude participation in this study.
  • Participant has any medical condition, personal circumstance, or ongoing AE (from an antecedent study) that, in the opinion of the investigator, exposes the participant to unacceptable risk by participating in the study or prevents adherence to the protocol.
  • Participant is pregnant, breastfeeding, or planning to become pregnant.
  • Participant is planning to enter a clinical study with a different drug or planning to use any experimental device for the treatment of any medical condition during the study or within 28 days after completion of this study.
  • Participant is judged by the investigator to have a significant risk for self-harm or suicidal behavior during their participation in the study or is considered to be an imminent danger to themself or others.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Azetukalner 20 mg

    Drug: Azetukalner

Interventions

  • Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 52 weeks.

06

What researchers measure

Primary outcomes

  1. Severity and frequency of treatment-emergent adverse events, serious adverse events, adverse events of special interest, and events of clinical interest

    Time frame: From the start of treatment in the open-label extension study through 8 weeks after the last dose

Secondary outcomes

  1. Change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score over time

    Time frame: From baseline through the active extension treatment (Week 52)

  2. Change in Clinical Global Impression of Severity (CGI-S) score over time

    Time frame: From baseline through the active extension treatment (Week 52)

  3. Change from baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) total score over time

    Time frame: From baseline through the active extension treatment (Week 52)

07

Study locations

20 sites
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jun 2029, 44 months after the start.

Of 29 industry-sponsored phase 3 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 49. This study's planned 44 months is above that.

Counting every sponsor, half of 43 studies reached it within 37 months; a quarter within 21 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2025
First posted
Oct 20, 2025
StartActual
Oct 30, 2025
Primary completionEst.
Jun 2029
CompletionEst.
Aug 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Active, not recruiting
changed Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Enrolling by invitation→Active, not recruiting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07217860
Responsible party
Sponsor
First posted
Oct 20, 2025
Start date
Oct 30, 2025
Primary completion
Jun 2029 (estimated)
Completion
Aug 2029 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: XEN1101

Start the discussion